Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.

PURPOSE To assess long-term outcomes of men with favorable-risk prostate cancer in a prospective, active-surveillance program. METHODS Curative intervention was recommended for disease reclassification to higher cancer grade or volume on prostate biopsy. Primary outcomes were overall, cancer-specific, and metastasis-free survival. Secondary outcomes were the cumulative incidence of reclassification and curative intervention. Factors associated with grade reclassification and curative intervention were evaluated in a Cox proportional hazards model. RESULTS A total of 1,298 men (median age, 66 years) with a median follow-up of 5 years (range, 0.01 to 18.00 years) contributed 6,766 person-years of follow-up since 1995. Overall, cancer-specific, and metastasis-free survival rates were 93%, 99.9%, and 99.4%, respectively, at 10 years and 69%, 99.9%, and 99.4%, respectively, at 15 years. The cumulative incidence of grade reclassification was 26% at 10 years and was 31% at 15 years; cumulative incidence of curative intervention was 50% at 10 years and was 57% at 15 years. The median treatment-free survival was 8.5 years (range, 0.01 to 18 years). Factors associated with grade reclassification were older age (hazard ratio [HR], 1.03 for each additional year; 95% CI, 1.01 to 1.06), prostate-specific antigen density (HR, 1.21 per 0.1 unit increase; 95% CI, 1.12 to 1.46), and greater number of positive biopsy cores (HR, 1.47 for each additional positive core; 95% CI, 1.26 to 1.69). Factors associated with intervention were prostate-specific antigen density (HR, 1.38 per 0.1 unit increase; 95% CI, 1.22 to 1.56) and a greater number of positive biopsy cores (HR, 1.35 for one additional positive core; 95% CI, 1.19 to 1.53). CONCLUSION Men with favorable-risk prostate cancer should be informed of the low likelihood of harm from their diagnosis and should be encouraged to consider surveillance rather than curative intervention.

[1]  Michael J. Barry,et al.  Screening for prostate cancer with the prostate-specific antigen test: a review of current evidence. , 2014, JAMA.

[2]  P. Carroll,et al.  Prostate cancer early detection, version 1.2014. Featured updates to the NCCN Guidelines. , 2014, Journal of the National Comprehensive Cancer Network : JNCCN.

[3]  Robert J Volk,et al.  Physician variation in management of low-risk prostate cancer: a population-based cohort study. , 2014, JAMA internal medicine.

[4]  Misop Han,et al.  Predicting 15-year prostate cancer specific mortality after radical prostatectomy. , 2011, The Journal of urology.

[5]  M. Cooperberg,et al.  Active surveillance for prostate cancer: a systematic review of the literature. , 2012, European urology.

[6]  D. Siemens.  Radical prostatectomy or watchful waiting in early prostate cancer? , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[7]  M. Roobol,et al.  Active surveillance for low-risk prostate cancer worldwide: the PRIAS study. , 2013, European urology.

[8]  Jennifer L. Beebe-Dimmer,et al.  Prognostic Gleason grade grouping : data based on the modified Gleason scoring system , 2013 .

[9]  W. Isaacs,et al.  Tracking the clonal origin of lethal prostate cancer. , 2013, The Journal of clinical investigation.

[10]  Matthew R Cooperberg,et al.  Time trends and local variation in primary treatment of localized prostate cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Corso,et al.  National Institutes of Health State-of-the-Science Conference: Role of Active Surveillance in the Management of Men With Localized Prostate Cancer , 2012, Annals of Internal Medicine.

[12]  Danny Vesprini,et al.  Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  William A Ghali,et al.  Kaplan-Meier methods yielded misleading results in competing risk scenarios. , 2006, Journal of clinical epidemiology.

[14]  P. Maté Mate.  [Radical prostatectomy versus observation for localized prostate cancer]. , 2013, Revista clinica espanola.

[15]  Mohammad Hassan Murad,et al.  Early detection of prostate cancer: AUA Guideline. , 2013, The Journal of urology.

[16]  A. Partin,et al.  African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  P. Walsh,et al.  Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. , 1994, JAMA.

[18]  Kirsten L. Greene,et al.  Extended followup and risk factors for disease reclassification in a large active surveillance cohort for localized prostate cancer. , 2015, The Journal of urology.

[19]  David C. Miller,et al.  Contemporary use of initial active surveillance among men in Michigan with low-risk prostate cancer. , 2015, European urology.

[20]  T. Tammela,et al.  Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up , 2014, The Lancet.

[21]  P. Carroll,et al.  Canary Prostate Active Surveillance Study: design of a multi-institutional active surveillance cohort and biorepository. , 2010, Urology.

[22]  P. Carroll,et al.  20-year outcomes following conservative management of clinically localized prostate cancer , 2005 .

[23]  T. Gomes,et al.  National Institutes of Health State-of-the-Science Conference: role of active surveillance in the management of men with localized prostate cancer. , 2012 .

[24]  A. Partin,et al.  Serum prostate‐specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density , 2014, BJU international.

[25]  P. Carroll,et al.  Prostate cancer early detection version 1 , 2014 .

[26]  V. Moyer,et al.  Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement , 2012, Annals of Internal Medicine.